Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 3/20 | 0.37 |
| ▸ | FNTA | P49354 | 4/20 | 0.36 |
| ▸ | FNTB | P49356 | 4/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980367 | 0.88 | BACE1 (0.47) | BACE1SIRT2SIRT5CTSDBACE2 | |
| SCHEMBL29749577 | 0.84 | METAP2 (0.42) | BACE1METAP2METAP1CTSDFNTA | |
| SCHEMBL30011225 | 0.84 | FNTA (0.44) | FNTAFNTB | |
| SCHEMBL31069710 | 0.84 | BACE1 (0.44) | BACE1CTSDBACE2 | |
| SCHEMBL29630546 | 0.82 | BACE1 (0.42) | BACE1PDCD1LG2CD274CTSDFNTA | |
| SCHEMBL30051216 | 0.81 | FNTA (0.46) | BACE1CTSDFNTAFNTB | |
| SCHEMBL31331637 | 0.81 | FNTA (0.46) | METAP2METAP1FNTAFNTB | |
| SCHEMBL30010983 | 0.81 | METAP2 (0.44) | BACE1METAP2METAP1CTSDFNTA | |
| SCHEMBL29588273 | 0.81 | FNTA (0.46) | METAP2METAP1FNTAFNTB | |
| SCHEMBL30980378 | 0.81 | BACE1 (0.48) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073446-A1 | Antigen Delivery Vectors and Constructs | ALTIMMUNE UK LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073446-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | BACE1 3511/4885METAP2 862/4885METAP1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.